The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced RCC

A summary of frontline treatment options for metastatic renal cell carcinoma and the rationale for the combination of lenvatinib plus pembrolizumab.

Results of the efficacy and safety data demonstrated by the CLEAR study of lenvatinib plus pembrolizumab or everolimus as first-line treatment for metastatic renal cell carcinoma.

Dr Moshe Ornstein examines dosing considerations for the combination of lenvatinib plus pembrolizumab in clinical practice and how that compares with the findings from the CLEAR study.

Implications for treating patients with metastatic renal cell carcinoma with frontline lenvatinib plus pembrolizumab based on the regimen’s performance in the CLEAR study compared with other treatment options.

An overview of data demonstrated by other investigational studies of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Discussing future needs and investigating novel therapies for newly diagnosed metastatic renal cell carcinoma.